Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
NeurAxis, Inc. ( (NRXS) ) has provided an announcement.
On July 1, 2025, NeurAxis, Inc. terminated its License and Collaboration Agreement with Masimo Corporation, which had been in place since April 9, 2020, for the NSS-2 Bridge device. As part of the termination, NeurAxis agreed to pay Masimo $200,000, resulting in the cessation of licensing payments and revenue from the device. Additionally, NeurAxis adopted a new Employee Stock Purchase Plan on the same date, allowing employees to purchase company stock at a discount, with stockholder approval required within 12 months.
The most recent analyst rating on (NRXS) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on NeurAxis, Inc. stock, see the NRXS Stock Forecast page.
Spark’s Take on NRXS Stock
According to Spark, TipRanks’ AI Analyst, NRXS is a Neutral.
The overall stock score is primarily impacted by significant financial risks, including negative equity and cash flow challenges. While technical analysis shows a neutral trend, and valuation metrics are weak, the earnings call provided optimistic guidance with potential for revenue growth and strategic advancements.
To see Spark’s full report on NRXS stock, click here.
More about NeurAxis, Inc.
NeurAxis, Inc. operates in the medical device industry, focusing on products that address opioid withdrawal symptoms. Its primary product, the NSS-2 Bridge, is a percutaneous nerve field stimulator used to alleviate opioid withdrawal symptoms.
Average Trading Volume: 1,660,738
Technical Sentiment Signal: Sell
See more insights into NRXS stock on TipRanks’ Stock Analysis page.